Unknown

Dataset Information

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.


ABSTRACT:

Background

Patients with light chain (AL) amyloidosis who present with severe heart failure due to cardiac involvement rarely survive more than 6 months. Survival after cardiac transplantation is markedly reduced due to the progression of amyloidosis. Autologous stem-cell transplantation (ASCT) has become a common therapy for AL amyloidosis, but there is an exceedingly high treatment-related mortality in patients with heart failure.

Methods

We developed a treatment strategy of cardiac transplant followed by ASCT. Twenty-six patients were evaluated, and of 18 eligible patients, nine patients underwent cardiac transplantation. Eight of these patients subsequently received an ASCT.

Results

Six of seven evaluable patients achieved a complete hematologic remission, and one

SUBMITTER: Dey BR 

PROVIDER: S-EPMC2964067 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature